Follow-up of patients with low-risk papillary thyroid carcinoma and undetectable basal serum thyroglobulin after ablation measured with a sensitive assay: A prospective study

Hormone and Metabolic Research

Volumn 45, Issue 12, 2013, Pages 911-914

  Rosario, P W S ^a   Dos Santos, J B N ^a   Calsolari, M R ^a  

^a Endocrinology Service   (Brazil)

Author keywords

long term follow up; low risk patients; sensitive thyroglobulin assay; thyroglobulin stimulation

Indexed keywords

IODINE 131; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROTROPIN;

ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CHEMOLUMINESCENCE; CONCENTRATION (PARAMETERS); ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LOW RISK POPULATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; SENSITIVITY ANALYSIS; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; TUMOR ABLATION;

ABLATION TECHNIQUES; ADOLESCENT; ADULT; AGED; CARCINOMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84887846079     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0033-1347264     Document Type: Article

References (19)

1. Cooper D. S., Doherty G. M., Haugen B. R., Kloos R. T., Lee S. L., Mandel S. J., Mazzaferri E. L., McIver B., Pacini F., Schlumberger M., Sherman S. I., Steward D. L., Tuttle R. M. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid: 2009; 19 1167 1214
2. NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma version 1.2013 www.nccn.org
3. Brassard M., Borget I., Edet-Sanson A., Giraudet A. L., Mundler O., Toubeau M., Bonichon F., Borson-Chazot F., Leenhardt L., Schvartz C., Dejax C., Brenot-Rossi I., Toubert M. E., Torlontano M., Benhamou E., Schlumberger M. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab: 2011; 96 1352 1359
4. Giovanella L., Ceriani L., Ghelfo A., Maffioli M., Keller F., Spriano G. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant thyrotropin stimulated assay and imaging procedures. Clin Chem Lab Med: 2006; 44 648 652 (Pubitemid 43735641)
5. Iervasi A., Iervasi G., Ferdeghini M., Solimeo C., Bottoni A., Rossi L., Colato C., Zucchelli G. C. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin Endocrinol (Oxf): 2007; 67 434 441 (Pubitemid 47283844)
6. Rosario P. W., Purisch S. Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4 <1 ng/ml determined by traditional assays? Clin Endocrinol (Oxf): 2008; 68 338 342 (Pubitemid 351257849)
7. Spencer C., Fatemi S., Singer P., Nicoloff J., Lopresti J. Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid: 2010; 20 587 595
8. Malandrino P., Latina A., Marescalco S., Spadaro A., Regalbuto C., Fulco R. A., Scollo C., Vigneri R., Pellegriti G. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. J Clin Endocrinol Metab: 2011; 96 1703 1709
9. Castagna M. G., Tala Jury H. P., Cipri C., Belardini V., Fioravanti C., Pasqui L., Sestini F., Theodoropoulou A., Pacini F. The use of ultrasensitive thyroglobulin assays reduces but not abolishes the need for TSH stimulation in patients with differentiated thyroid carcinoma. J Endocrinol Invest: 2011; 34 219 223
10. Chindris A. M., Diehl N. N., Crook J. E., Fatourechi V., Smallridge R. C. Undetectable sensitive serum thyroglobulin (<0.1 ng/ml) in 163 patients with follicular cell-derived thyroid cancer: results of rhTSH stimulation and neck ultrasonography and long-term biochemical and clinical follow-up. J Clin Endocrinol Metab: 2012; 97 2714 2723
11. Giovanella L., Maffioli M., Ceriani L., De Palma D., Spriano G. Unstimulated high sensitive thyroglobulin measurement predicts outcome of differentiated thyroid carcinoma. Clin Chem Lab Med: 2009; 47 1001 1004
12. Mazzaferri E. L. Will highly sensitive thyroglobulin assays change the management of thyroid cancer? Clin Endocrinol (Oxf): 2007; 67 321 323 (Pubitemid 47283837)
13. Giovanella L. Highly sensitive thyroglobulin measurements in differentiated thyroid carcinoma management. Clin Chem Lab Med: 2008; 46 1067 1073
14. McLeod D. S. Current concepts and future directions in differentiated thyroid cancer. Clin Biochem Rev: 2010; 31 9 19
15. Rosario P. W., Faria S., Bicalho L., Gatti Alves M. F., Borges MA R., Purisch S., Padrão E. L., Rezende L. L., Barroso A. L. Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J Ultrasound Med: 2005; 24 1385 1389 (Pubitemid 41395927)
16. Durante C., Montesano T., Torlontano M., Attard M., Monzani F., Tumino S., Costante G., Meringolo D., Bruno R., Trulli F., Massa M., Maniglia A., D'Apollo R., Giacomelli L., Ronga G., Filetti S. on behalf of the PTC Study Group Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. J Clin Endocrinol Metab: 2013; 98 636 642
17. Rosario P. W., Mineiro Filho A. F. Does undetectable basal Tg measured with a highly sensitive assay in the absence of antibodies and combined with normal ultrasonography ensure the absence of disease in patients treated for thyroid carcinoma? Arq Bras Endocrinol Metabol: 2012; 56 149 151
18. Rosario P. W. Ultrasonography for the follow-up of patients with papillary thyroid carcinoma: how important is the operator? Thyroid: 2010; 20 833 834
19. Cailleux A. F., Baudin E., Travagli G. P., Richard M., Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab: 2000; 85 175 178 (Pubitemid 32268810)